NAFLD/MASLD和肠肝轴:从致病源到治疗选择
Natalia G Vallianou1, Dimitris Kounatidis2, Sotiria Psallida3
1First Department of Internal Medicine, Sismanogleio General Hospital, Sismanogliou 1 Str., 15126 Athens, Greece.
与代谢功能障碍相关的脂肪性肝病 (MASLD),以前称为非酒精性脂肪性肝病 (NAFLD),与肠道微生物群的变化有关. 调节肠道细菌显示出治疗潜力,特别是在瘦身患者中,但需要进一步的安全研究.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 微生物学 微生物学
- 胃肠病学 胃肠病学
背景情况:
- 非酒精性脂肪性肝病 (NAFLD),现在被称为代谢功能障碍相关的脂肪性肝病 (MASLD),是一个日益严重的公共卫生问题.
- 非酒精性脂肪肝炎 (NASH) 是西方国家肝癌的主要原因.
- 肠肝轴,一种双向通信通道,在NAFLD/MASLD病原体中越来越被认可.
研究的目的:
- 审查肠道微生物群改变在NAFLD/MASLD中的作用.
- 探索肠道微生物群调节策略的治疗潜力.
- 讨论新术语 (MASLD与NAFLD) 的影响.
主要方法:
- 文献综述侧重于肠肝轴的研究.
- 针对肠道微生物群的治疗干预措施的分析.
- 检查新兴的治疗方法,如益生菌,益生菌,共生菌,后生菌,菌体和便微生物群移植.
主要成果:
- 肠道失调是NAFLD/MASLD发展的一个重要因素.
- 下一代益生菌和基因工程细菌显示出有希望的结果.
- 微生物群调节方法可能为瘦体NAFLD/MASLD患者提供治疗选择.
结论:
- 肠道微生物群调节为NAFLD/MASLD提供了潜在的治疗途径.
- 进一步的大规模研究至关重要,以确认这些干预措施的有效性和安全性.
- 关于NAFLD/MASLD术语的辩论强调了对这种疾病的不断变化的理解.
更多相关视频
08:41Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
Published on: March 24, 2023
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Chronic Pancreatitis II: Collaborative Care
Assessment:
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Ulcerative Colitis in IBD
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
